Supply Chain

Danaher will purchase Cepheid, a medical diagnostics company located in Sunnyvale, Calif., for a value of $4 billion, according to Reuters.

The Food and Drug Administration granted orphan drug status to Firdapse, an experimental treatment for patients with myasthenia gravis, a degenerative neuromuscular disease similar to Parkinson's or Lou Gehrig's disease, according to South Florida Business Journal.

The Food and Drug Administration will allow two clot retrieval devices to be used in conjunction with a clot-dissolving drug as an initial treatment for strokes caused by blood clots.

The Food and Drug Administration granted Fast Track designation for aducanumab, an experimental Alzheimer's drug created by Cambridge, Mass.-based Biogen, reports the Boston Herald.

Disposable supplies are often left over at the end of neurosurgical procedures. A recent study has identified the costs associated with discarding these opened but unused surgical supplies.

A large study found many diabetic individuals who self-administer insulin are incorrectly injecting the treatment, prompting experts to create formal recommendations, Reuters reported.

Kenilworth, N.J.-based Merck will stop developing its experimental drug to treat osteoporosis following an analysis showing the drug is tied to increased stroke risk.

Democratic presidential nominee Hillary Clinton unveiled a plan in response to "unjustified" price increases for long-available prescription drugs like EpiPens, according to a campaign release. 

Sunovion Pharmaceuticals, based in Marlborough, Mass., will acquire Toronto-based Cynapsus Therapeutics for $624 million.

Swiss drugmaker Roche hopes to earn Food and Drug Administration approval to treat non-small cell lung cancer patients with its bladder cancer treatment Tecentriq, reported Reuters.